Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.1079
Abstract: 1079 Background: Tumors develop resistance following 1L endocrine therapy (ET) + CDK4/6i in ER+/HER2- mBC. Elacestrant (Ela) significantly improved PFS vs standard-of-care (SOC) ET ( ESR1 -mut tumors HR 0.55; 95% CI 0.39-0.77; P=0.0005; all… read more here.
Keywords: ela; nausea; ela 345; pts her2 ... See more keywords